1. Home
  2. DOCN vs ABVX Comparison

DOCN vs ABVX Comparison

Compare DOCN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DigitalOcean Holdings Inc.

DOCN

DigitalOcean Holdings Inc.

HOLD

Current Price

$141.91

Market Cap

13.2B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$94.90

Market Cap

11.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOCN
ABVX
Founded
2011
2013
Country
United States
France
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
11.9B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
DOCN
ABVX
Price
$141.91
$94.90
Analyst Decision
Buy
Buy
Analyst Count
14
13
Target Price
$85.46
★ $131.31
AVG Volume (30 Days)
★ 2.3M
1.2M
Earning Date
05-05-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 183.15
N/A
EPS
★ 0.45
N/A
Revenue
★ $901,427,000.00
N/A
Revenue This Year
$23.80
$52.14
Revenue Next Year
$30.11
$4,132.27
P/E Ratio
$313.80
★ N/A
Revenue Growth
★ 15.48
N/A
52 Week Low
$33.69
$69.81
52 Week High
$187.50
$148.83

Technical Indicators

Market Signals
Indicator
DOCN
ABVX
Relative Strength Index (RSI) 58.34 N/A
Support Level $106.83 N/A
Resistance Level $140.15 N/A
Average True Range (ATR) 9.38 0.00
MACD 2.68 0.00
Stochastic Oscillator 69.79 0.00

Price Performance

Historical Comparison
DOCN
ABVX

About DOCN DigitalOcean Holdings Inc.

DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: